Galunisertib
Galunisertib is a pharmaceutical drug with 11 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
90.0%
9 of 10 finished
10.0%
1 ended early
0
trials recruiting
11
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study in Recurrent Glioblastoma (GB)
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
Clinical Trials (11)
A Study in Recurrent Glioblastoma (GB)
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
A Study of Galunisertib in Participants With Myelodysplastic Syndromes
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
A Study of Galunisertib on the Immune System in Participants With Cancer
Study of Galunisertib in Healthy Participants
All 11 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 11